David Koos - Regen BioPharma Chairman
| RGBP Stock | USD 0.06 0 8.17% |
Chairman
Mr. David R. Koos is a Chairman of the Board, Chief Executive Officer, Treasurer, Secretary of REGEN BIOPHARMA INC. He was Chief Financial Officer of Regen BioPharma Inc. Previously he was Chairman, President, Chief Executive Officer, Secretary, Chief Financial Officer and Principal Accounting Officer at Entest BioMedical, Inc. from June 19, 2009 to the current day . He served as Chief Financial Officer, Principal Accounting Officer at Entest BioMedical, Inc. from June 19, 2009 to March 31, 2010 . He served as Acting Chief Financial Officer, Principal Accounting Officer at Entest BioMedical, Inc from August 8, 2011 to current day. He is Chairman, President, CEO and Acting CFO of BioMatrix Scientific Group, Inc. Since June 14, 2006 to Present and from June 19, 2006 as President, CEO and Acting CFO. from June 19, 2006 as Secretary till date. Prior to that he served as Chairman, CEO, Secretary Acting CFO of Frezer Inc. from May 2, 2005 to February 2007. He also worked as Chairman, CEO Acting CFO of BMXP Holdings, Inc. from December 6, 2004 to June 2008. since 2015.
| Age | 62 |
| Tenure | 9 years |
| Phone | 619 722 5505 |
| Web | https://regenbiopharmainc.com |
Regen BioPharma Management Efficiency
The company has return on total asset (ROA) of (0.7581) % which means that it has lost $0.7581 on every $100 spent on assets. This is way below average. Regen BioPharma's management efficiency ratios could be used to measure how well Regen BioPharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
Management Performance
| Return On Asset | -0.76 |
Regen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Regen BioPharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 22.4 M | |||
| Shares Outstanding | 5.05 B | |||
| Shares Owned By Insiders | 0.06 % | |||
| Price To Sales | 89.73 X | |||
| Revenue | 235.52 K | |||
| Gross Profit | 235.52 K | |||
| EBITDA | 2.44 M |
Pair Trading with Regen BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Regen Pink Sheet
| 0.42 | PLTR | Palantir Technologies Aggressive Push | PairCorr |
| 0.37 | AMKBY | AP Moeller Maersk | PairCorr |
| 0.33 | BRK-A | Berkshire Hathaway | PairCorr |
The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.